Novocure to Participate in 43rd Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

Novocure (NASDAQ: NVCR) has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference scheduled for Wednesday, January 15, 2025. CEO Ashley Cordova and Executive Chairman William Doyle will represent the company, delivering a presentation at 9:00 a.m. PST and addressing questions.

The executives, along with CFO Christoph Brackmann, will conduct one-on-one meetings with investors throughout the conference. A live audio webcast of the presentation will be accessible through Novocure's Investor Relations webpage and will remain available for replay for at least 14 days after the event.

BAAR, Switzerland--(BUSINESS WIRE)-- Novocure (NASDAQ: NVCR) announced today that management will participate in the 43^rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025. Ashley Cordova, Chief Executive Officer, and William Doyle, Executive Chairman, will speak on behalf of the company and address questions at 9:00 a.m. PST. Ms. Cordova and Mr. Doyle will be joined by Christoph Brackmann, Chief Financial Officer, for one-on-one meetings with investors throughout the conference.

A live audio webcast of this presentation can be accessed from the Investor Relations page of Novocure’s website, www.novocure.com/investor-relations, and will be available for replay for at least 14 days following the event.

About Novocure
Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of its innovative therapy, Tumor Treating Fields. Novocure’s commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma, non-small cell lung cancer, malignant pleural mesothelioma and pleural mesothelioma. Novocure has several additional ongoing or completed clinical trials exploring the use of Tumor Treating Fields therapy in the treatment of glioblastoma, non-small cell lung cancer and pancreatic cancer.

Novocure’s global headquarters is located in Baar, Switzerland, with U.S. headquarters located in Portsmouth, New Hampshire and research and development facilities located in Haifa, Israel. For additional information about the company, please visit Novocure.com and follow @Novocure on LinkedIn and Twitter.

Forward-Looking Statements
In addition to historical facts or statements of current condition, this press release may contain forward-looking statements. Forward-looking statements provide Novocure’s current expectations or forecasts of future events. These may include statements regarding anticipated scientific progress on its research programs, clinical trial progress, development of potential products, interpretation of clinical results, prospects for regulatory approval, manufacturing development and capabilities, market prospects for its products, coverage, collections from third-party payers and other statements regarding matters that are not historical facts. You may identify some of these forward-looking statements by the use of words in the statements such as “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe” or other words and terms of similar meaning. Novocure’s performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, environmental, regulatory and political conditions and other more specific risks and uncertainties facing Novocure such as those set forth in its Annual Report on Form 10-K filed on February 22, 2024, and subsequent filings with the U.S. Securities and Exchange Commission. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements. Furthermore, Novocure does not intend to update publicly any forward-looking statement, except as required by law. Any forward-looking statements herein speak only as of the date hereof. The Private Securities Litigation Reform Act of 1995 permits this discussion.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250103444578/en/

INVESTORS:

Ingrid Goldberg

investorinfo@novocure.com

MEDIA:

Catherine Falcetti

media@novocure.com

Source: Novocure

FAQ

When is Novocure (NVCR) presenting at the 2025 J.P. Morgan Healthcare Conference?

Novocure will present on Wednesday, January 15, 2025, at 9:00 a.m. PST during the 43rd Annual J.P. Morgan Healthcare Conference.

Who will represent NVCR at the 2025 J.P. Morgan Healthcare Conference?

CEO Ashley Cordova and Executive Chairman William Doyle will speak on behalf of Novocure, with CFO Christoph Brackmann joining for investor meetings.

How can investors access Novocure's J.P. Morgan Healthcare Conference presentation?

Investors can access the live audio webcast through Novocure's Investor Relations website at www.novocure.com/investor-relations.

How long will NVCR's J.P. Morgan Conference presentation replay be available?

The presentation replay will be available for at least 14 days following the event on Novocure's Investor Relations website.

Will NVCR management be available for individual investor meetings at the conference?

Yes, CEO Ashley Cordova, Executive Chairman William Doyle, and CFO Christoph Brackmann will conduct one-on-one meetings with investors throughout the conference.